#1JAGUA NATION Amedisys Fourth Quarter 2021 Earnings Call Supplemental Slides February 24th, 2022 + amedisys 1#2Forward-looking statements This presentation may include forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions about our business that are subject to a variety of risks and uncertainties that could cause actual results to differ materially from those described in this presentation. You should not rely on forward-looking statements as a prediction of future events. Additional information regarding factors that could cause actual results to differ materially from those discussed in any forward-looking statements are described in reports and registration statements we file with the SEC, including our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, copies of which are available on the Amedisys internet website http://www.amedisys.com or by contacting the Amedisys Investor Relations department at (225) 292-2031. We disclaim any obligation to update any forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based except as required by law. www.amedisys.com NASDAQ: AMED We encourage everyone to visit the Investors Section of our website at www.amedisys.com, where we have posted additional important information such as press releases, profiles concerning our business and clinical operations and control processes, and SEC filings. 2#3• A Look Back FY 2021 Accomplishments Clinical Distinction Maintained at least 95% of all Home Health care centers achieving 4.0+ Quality of Patient Care star score Outperformed industry on all hospice item set (HIS) quality metrics Outstanding Outcomes for Our Patients (+) Amedisys Care Centers and Clinical Team CLINICAL DISTINCTION EMPLOYER OF CHOICE OPERATIONAL EXCELLENCE & EFFICIENCY DRIVING GROWTH • Employer of Choice • Ended the year with overall voluntary turnover of 19.4% (FY'21) While the industry is reporting record increases in nursing turnover; in 2021, we reduced our nursing turnover to 26.8% from 29.5% in 2020, a 9% YoY reduction Operational Excellence and Efficiency • . Grew EBITDA by 10% from $273.5M in 2020 to $299.6M in 2021 Expanded consolidated EBITDA margin 40 bps to 13.6% (FY'21) despite continuing impacts from COVID-19 Delivered $189M in cash flow from operations Driving Growth • • • Grew Home Health same store total admissions +6% and Hospice same store total admissions +2% Acquired four CONS and VNA (Home Health in Omaha, NE) Acquired Contessa Health (closed in August 2021) Contessa subsequently signed new JV partnerships with Henry Ford Health Plan and Penn State Health 3#4Our Key Areas of Focus Strategic areas of focus and progress made during Q4'21 1 3 4 5 6 • • Organic Growth Home Health*: Total same store admissions +2%, Total same store volume +2% Hospice: Total same store Admissions -1%, ADC-4% • Personal Care: PC Network drove ~$522K in revenue to Home Health and Hospice via care coordination Recruiting/ Retention • Targeting industry leading employee retention amongst all employee categories • Q4'21 Voluntary Turnover 21.5% • 533 Hospice BD FTE's as of YE'21 (+52 over PY) 877 Home Health BD FTE's as of YE'21 (+37 over PY) . . Clinical Initiatives • Quality: Amedisys Jan'22 release STARS score of 4.33 (SHP: 4.5 STARS) 95% of care centers at 4+ Stars based on internal calculation • 37 Amedisys care centers rated at 5 Stars in the Jan'22 Release Hospice quality - outperforming industry average in all hospice item set (HIS) categories Capacity and Productivity ⚫ Focusing on optimizing RN/ LPN & PT/PTA staffing ratios. • Current LPN Ratio: 49.0% (vs. 47.5% in 4Q'20) • Current PTA Ratio: 52.9% (vs. 50.9% in 4Q'20) • • . M&A Signed a new Hospital at Home JV with Penn State Health (11/10/21) Signed the acquisition of Evolution Health on 2/1/22 expanding our footprint in TX, OK and OH (15 care - centers) expected to close summer of 2022 Signed Assisted Care Home Health (2 locations in North Carolina) on 2/21/22 ::M:! Regulatory 2021 Reimbursement Final Home Health industry rule net +1.9% increase Final Hospice industry rule net +2.4% increase (effective 10/1/20) 2022 Reimbursement • Final Home Health . • industry rule net +3.2% increase Final Hospice industry rule net +2.0% increase (effective 10/1/21) Sequestration suspension extended until 6/30/22. Full 2% for three months reduced to 1% for remaining three months *Note: Home Health same store volume is defined as admissions plus recertifications 4#5Highlights and Summary Financial Results (Adjusted): 4Q 2021(1) Home Health total same store volume +2%, total same store admissions +2%; Hospice same store admissions -1%; Margin pressure driven by Hospice ADC decline & labor costs amedisys Adjusted Financial Results Amedisys Consolidated $ in Millions, except EPS . Revenue Growth: +2% ⚫ EBITDA: $65M (-17%, ex. • Contessa -10%) EBITDA Margin: 11.6% (ex. Contessa: 12.6%) ⚫EPS: $1.18 (-21%) Home Health Hospice Personal Care High Acuity Care Total Revenue Gross Margin % Adjusted EBITDA Home Health Same Store (2)(3): • Total Volume: +2% Adjusted EPS Free cash flow (4) Hospice Same Store Volume (3): 4Q20 4Q21 FY 2020 FY 2021 329.4 337-3 203.9 204.9 17.4 15.1 1,249.2 750.1 72.2 1,353.8 785.3 65.0 2.0 3.5 $ 550.7 $ 559.3 $ 2,071.5 $ 2,207.6 45.5% 44.1% 44.6% 45.1% Balance Sheet & Cash Flow • Net debt: $403.8M • Net Leverage ratio: 1.3x • Revolver availability: $522.5M • CFFO: $5.2M 78.1 64.8 273.5 299.6 • Free cash flow (4): $1.2M 14.2% 11.6% 13.2% 13.6% • DSO: 43.2 (vs. Q4'20 of. 40.2 and $1.49 $1.18 $6.11 $5.95 down 0.3 days since Q3) $60.6 $1.2 $273.5 $174.3 . Total Admissions: +2% Other Statistics: Revenue per Episode (5): $2,951 (+1.5%) • Admissions: -1% ADC: -4% Other Statistics: Revenue per Day: $168.24 (+4.7%) Total Cost per Visit: $106.67 (+5.9%) Cost per day: $90.23 (+10.8%) Personal Care Growth Metrics: Clients served: -22% High Acuity Care Growth Metrics: Billable hours/quarter: -24% • Total Admissions: 286 • Number of JV's: 8 Other Statistics: Other Statistics: • Revenue per hour: +15% Cost per hour: +17% • Patient Satisfaction: 97% 1. 23456 2. The financial results for the three-month periods and years ended December 31, 2020 and December 31, 2021 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period. Same Store volume - Includes admissions and recertifications. 3. Same Store is defined as care centers that we have operated for at least the last 12 months and startups that are an expansion of a same store care center. 4. 5. Free cash flow is defined as cash flow from operations less routine capital expenditures and required debt repayments. Q4'20 free cash flow includes payroll tax deferrals. Medicare sequestration suspended 5/1/20. 5#6• • • • • Our Revenue Sources: 4Q'21 Amedisys Consolidated Revenue Home Health Revenue 2.7% 0.4% Hospice Revenue 5.3% 19.1% 36.6% 12.7% 60.3% 68.2% Home Health Personal Care Hospice High Acuity Care Medicare FFS Private Episodic Per Visit 94.7% Medicare FFS Private Home Health: 331 care centers; 34 states & D.C. Hospice: 175 care centers; 34 states Personal Care: 14 care centers; 3 states High Acuity Care: 8 Joint Ventures; 6 states; 24 referring hospitals Total AMED: 528 care centers; 38 states and D.C. • Medicare FFS: Reimbursed over a 30-day period of care Private Episodic: MA and Commercial plans who reimburse us over a 30-day period of care, majority of which range from 95% - 100% of Medicare rates Per Visit: Managed care, Medicaid and private payors reimbursing us per visit performed . Hospice Per Day Reimbursement: • Routine Care: Patient at home with symptoms controlled ~97% of the Hospice care AMED provides, in line with overall hospice industry provision of care Continuous Care: Patient at home with uncontrolled symptoms • Inpatient Care: Patient in facility with uncontrolled symptoms • Respite Care: Patient at facility with symptoms controlled 6#7Home Health and Hospice Segment (Adjusted) - 4Q 2021 (1) Home Health total volume growth +2%; Hospice Admit Growth -1% HOME HEALTH HOSPICE Year Ended Year Ended $ in Millions 4Q20 4Q21 2020 2021 $ in Millions 4Q20 4Q21 2020 2021 Medicare Non-Medicare 228.3 230.1 101.1 Home Health Revenue 107.2 $329.4 $337.3 847.3 401.9 $1,249.2 914.5 439.3 $1,353.8 Medicare Non-Medicare Hospice Revenue 193.5 193.9 710.0 743.6 10.4 11.0 $203.9 $204.9 40.1 $750.1 41.7 $785.3 Gross Margin % Pre-Corporate EBITDA (2) 44.2% $65.2 $62.9 19.8% 18.7% 43.8% 43.5% 45.1% Gross Margin % 49.3% 46.4% 48.3% $236.7 $281.6 Pre-Corporate EBITDA (2) $52.7 $41.0 $187.4 46.9% $169.7 19.0% 20.8% 25.8% 20.0% 25.0% 21.6% Operating Statistics Operating Statistics Same Store Growth (3)(4) Total Volume 5% Total Admissions 6% do do 2% 2% 5% Admit growth - same store (4) ADC growth - same store (4) 15% -1% 6% 2% 0% -4% 1% -4% 2% 1% 6% ADC 13,793 Avg. discharge length of stay 102 13,237 90 13,081 13,271 99 94 Medicare Revenue per Episode (5) $2,906 $2,951 2,836 $ 2,959 Medicare Recert Rate 34.5% 35.1% 36.3% 35.1% $100.69 $106.67 $95.59 $101.46 Revenue per day (net) Cost per day $160.72 $168.24 $81.45 $90.23 $156.69 $162.12 $81.02 $86.15 Total Cost per visit • • Home Health Highlights Revenue per Episode up 1.5% (+1.9% rate increase effective 1/1/2021) Y/Y CPV up $5.98 (+5.9%, primarily due to raises, new hire pay, clinician bonuses, wage inflation and health insurance) Visits per Episode decreased 0.3 Hospice Highlights Net revenue per day +4.7% (primarily due to +2.0% Hospice rate update effective 10/1/2021 and favorable cap adjustments) 1. 2345 2. 3. 4. 5. The financial results for the three-month periods and years ended December 31, 2020 and December 31, 2021 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period. Pre-Corporate EBITDA does not include any corporate G&A expenses. Same Store information represents the percent change in volume or admissions for the period as a percent of the volume or admissions of the prior period. Same Store is defined as care centers that we have operated for at least the last 12 months and startups that are an expansion of a same store care center. Average Medicare revenue per completed episode reflects the transition to PDGM effective Jan. 1, 2020 and the suspension of sequestration effective May 1, 2020. 7#8General & Administrative Expenses - Adjusted (1.2) Impacted by COVID-19, acquisitions and investments to drive volume growth $ in Millions 4Q20 1Q21 2Q21 3Q21 4Q21 Home Health Segment - Total Salary and Benefits 80.5 80.0 81.3 % of HH Revenue 24.4% 24.3% 23.3% 82.4 24.3% 84.7 Other 25.1% Corp. G&A Subtotal Non-cash comp Hospice Segment - Total 47.9 46.3 48.4 % of HSP Revenue 23.5% 24.2% 25.3% 49.5 25.1% 54.0 26.4% Adjusted Corporate G&A 4Q20 25.0 1Q21 2Q21 3Q21 4Q21 23.4 22.0 22.1 21.7 13.2 12.7 11.6 12.8 10.4 38.2 36.1 33.6 34.9 32.1 4.6 5.3 4.5 2.8 4.0 42.8 41.4 38.1 37.7 36.1 Total G&A as a Percent of Revenue Personal Care Segment - Total 3.0 % of PC Revenue 17.2% 3.1 18.2% 3.1 18.1% 2.6 2.4 34.0% 16.5% 15.7% 32.8% 31.6% 31.8% 31.8% High Acuity Care Segment - Total 32.0% 3.8 6.2 % of HAC Revenue -% -% -% 255.2% 30.7% 305.7% 30.0% Total Corporate Expenses 42.8 % of Total Revenue 7.8% 41.4 38.1 7.7% 6.8% 37.7 36.1 6.8% 6.5% 28.0% 4Q20 Total % of Total Revenue 174.2 31.6% 170.8 170.9 176.0 183.4 31.8% 30.7% 31.8% 32.8% 1Q21 2Q21 G&A as a Percent of Revenue 3Q21 4Q21 Notes: • • Year over year total G&A as a percentage of revenue increased 120 basis points ($9 million); 20 basis point ($3 million) increase excluding Contessa Increases related to the Contessa acquisition, raises, the addition of resources to support growth, higher travel and training spend and higher health insurance costs were offset by lower incentive compensation costs Total G&A as a percentage of revenue increased 100 bps sequentially 1. 2. The financial results for the three-month periods ended December 31, 2020, March 31, 2021, June 30, 2021, September 30, 2021 and December 31, 2021 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period. Adjusted G&A expenses do not include depreciation and amortization. 80#9Operational Excellence: Home Health Cost Per Visit (CPV)-Adjusted YOY Total CPV impacted by planned wage increases, wage inflation, new hire pay and higher health insurance costs. Contractor costs down slightly year over year as utilization has stabilized Components Salaries 4Q'20 3Q'21 4Q'21 YoY Variance $66.09 $67.58 $69.73 $3.64 Contractors $5.08 $4.96 $4.93 ($0.15) Benefits $12.98 $13.16 $14.52 $1.54 Detail YoY increase (+5.5%) due to higher fixed new hire pay (+1.9%), planned wage increases, wage inflation and clinician bonuses Sequential increase due to the same drivers, including one additional month of raises YoY and Sequential variances minimal due to relatively consistent utilization YoY increase due to the impact of COVID-19 on health insurance costs (lower utilization in prior year) Sequential increase due to the seasonality of claims Initiatives Staffing mix optimization, productivity and scheduling improvement initiatives in place to help overcome salary increases Focused efforts on filling positions with full-time clinicians Focus on cost containment and spend optimization with specific focus on high-cost claims Transportation & Supplies $7.16 $7.28 $7.10 ($0.06) *Visiting Clinician CPV $91.31 $92.98 Clinical Managers $9.38 $9.85 $96.28 $10.39 $4.97 $1.01 Fixed cost associated with non- visiting clinicians YoY increase driven by additional staff and planned wage increases Total CPV $100.69 $102.83 $106.67 $5.98 *Note: Direct comparison with industry competitors CPV calculation Unit cost reduced as volume increases $91.31 Cost Per Visit (CPV) $92.98 $96.28 $100.00 $75.00 $50.00 $25.00 4Q20 3Q21 4Q21 ■Salaries ■Contractors ■Benefits Transportation 6#10Driving Top Line Growth Home Health total volume, Hospice admissions and ADC, as well as Personal Care billable hours lagging due to prolonged COVID-19 impacts related to the Omicron variant (staffing challenges, increase in clinician quarantine and increase in hospice discharge rate) Home Health Total Volume Hospice Growth 150,000 100,000 5% 6% 12% HIH 15.0% 14,500 20% 1,000,000 12.0% 14,000 15% 15% 9.0% 800,000 1% 2% 6.0% 13,500 10% 5% 600,000 3.0% 13,000 0% 2% 5% 1% -3% 0.0% -1% 0% 400,000 12,500 50,000 -3.0% -5% -4% 4Q20 1Q21 2Q21 3Q21 4Q21 12,000 -5% -10% 200,000 Volume Q420 Q121 Q221 Q321 4Q21 YoY Same Store Growth ADC SS ADC Growth Admits SS Admit Growth Personal Care Total Hours / Quarter 0 4Q20 1Q21 2Q21 3Q21 4Q21 ■Billable Hours 10#11Industry Leading Quality Scores Quality of Patient Care (QPC) Patient Satisfaction (PS) Metric JAN 20 Release APR 20 Release OCT 20 Release JAN 22 Release Metric JAN 20 Release APR 20 Release OCT 20 JAN 20 Release Release Quality of Patient Care 4.27 4.26 4.33 4.33 Patient Satisfaction Star 3.71 3.79 4.28 3.60 Entities at 4+ Stars 86% 86% 92% 92% Performance Over Industry +6% +6% +7% +3% 4.50 QPC Industry Performance 4.00 3.50 3.00 JAN 16 OCT 16 JAN17 APR17 APR 16 JUL 16 Amedisys 4.50 CMS 4.00 Blind Period JUL17 OCT17 JAN18 APR18 JUL18 OCT18 QPC Industry Avg QPC Top Competitor JAN19 APR19 JUL19 OCT19 JAN20 APR20 OCT20 JAN21 APR21 JUL21 OCT21 JAN22 3.50 3.00 JAN 16 APR 16 JUL 16 OCT 16 JAN 17 APR 17 PS Industry Performance W CMS Blind Period JUL 17 OCT 17 JAN18 APR18 Amedisys PS Score PS Industry Avg PS Top Competitor JUL18 OCT18 JAN19 APR19 JUL19 OCT19 JAN20 APR20 OCT20 JAN21 APR21 JUL21 OCT21 JAN22 • Amedisys maintains a 4-Star average in the Jan 2022 HHC Release with 92% of our providers (representing 95% of care centers) at 4+ Stars and 61% of our providers (representing 67% of care centers) at 4.5+ Stars. ⚫25 Amedisys providers (representing 37 care centers) rated at 5 Stars. Notes: (1) CMS did not provide QPC Star and HH-CAHPS performance releases in 2021 due to COVID-19 PHE. (2) Jan 2022 QPC Star Release performance period = 7/1/2020 - 3/31/2021 (CY 2019 for ACH). (3) Jan 2022 HH-CAHPS Release performance period = 7/1/2020 - 6/30/2021. 11#12Hospice Quality: Amedisys Hospice Continues to Move Towards Best-in-Class Hospice Item Set (HIS) Preview - Feb 2022 Jul 2020 - Mar 2021 Discharges 100.0% 99.5% 99.7% 100.0% 100.0% 97.9% 97.7% 99.4% 93.6% 99.8% 98.9% 99.4% 99.9% 99.0% 97.3% 94.3% 92.8% 95.0% 90.0% 90.0% 82.6% 85.0% 80.0% 75.0% 70.0% 65.0% Treatment Preferences Beliefs / Values Addressed Pain Screening Pain Assessment Dyspnea Screening Dyspnea Treatment Patient Treated with an Opioid Who Are Given a Bowel Regimen * Hospice Visits When Death Is Imminent, Measure 1 Hospice and Palliative Care Composite Process Measure 95.0% 90.0% 85.0% 81.8% 81.0% 80.0% 78.3% 78.0% AMED CMS Nat Hospice CAHPS Preview - Feb 2022 Oct 2018 - Dec 2019; July 2020 - March 2021 Discharges 90.5% 91.0% 90.0% 90.0% 77.9% 76.2% 76.0% 75.0% 84.5% 84.0% 82.6% 82.0% 81.2% 81.0% 75.0% 70.0% 65.0% Communication Timely Care Treat with Respect Emo / Rel Support Help For Symptoms Hospice Training Rating of Hospice Care Willingness to Recommend CAHPS Roll-Up / Average AMED CMS Nat Notes: Included in the above analysis are active care centers. Acquired locations were only included if their acquisition date was before the start of the reporting window. Above excludes Asana, Aseracare, and CCH acquisitions. * Hospice Visits When Death is Imminent, Measure 1 is referencing discharges from Jan 2019 through Dec 2019 12#13Debt and Liquidity Metrics Net leverage ~1.3x Outstanding Debt Outstanding Revolver Outstanding Term Loan Promissory Notes Finance Leases Total Debt Outstanding Less: Deferred Debt Issuance Costs Total Debt - Balance Sheet Total Debt Outstanding Less Cash Net Debt (1) Leverage Ratio (net)' Credit Facility Term Loan Revolver Size Borrowing Capacity Revolver Size Outstanding Revolver Letters of Credit Available Revolver (2) Plus Cash Total Liquidity (3) As of: 12/31/21 447.2 0.8 1.6 449.6 (4.5) 445.1 449.6 (45.8) 403.8 1.3 As of: 12/31/21 450.0 550.0 1,000.0 1. Net debt defined as total debt outstanding ($449.6M) less cash ($45.8M). 2. Leverage ratio (net) is defined as net debt divided by last twelve months adjusted EBITDA ($299.6M). 3. Liquidity defined as the sum of cash balance and available revolving line of credit. 550.0 (27.5) 522.5 45.8 568.3 13#14Cash Flow Statement Highlights (1) ~ 2020 includes benefit of payroll tax deferral (COVID-19 relief). Total payroll tax deferral of $55M (half paid in December 2021; remainder due in December 2022). $ in Millions 4Q20 1Q21 2Q21 3Q21 4Q21 GAAP Net Income 45.6 50.3 80.6 45.2 34.0 Changes in working capital 34.5 (18.3) (9.1) (7.0) (27.1) Depreciation and amortization 8.8 7.6 6.7 7.5 9.1 Non-cash compensation, includes 401(k) match expense 7.0 7.3 6.2 4.4 5.9 Deferred income taxes (23.8) 7.4 15.3 12.0 9.9 Other (6.2) (0.3) (31.7) (0.3) (26.6) Cash flow from operations 65.9 54.0 68.0 61.8 5.2 Capital expenditures - routine (2.4) (1.6) (1.0) (2.2) (0.7) (2.9) (2.7) (2.7) (0.5) (3.3) 60.6 49.7 64.3 59.1 1.2 Required debt repayments Free cash flow Capital Deployment Acquisitions Share Repurchases Total 0.8 (2.5) (262.4) (5.1) (72.9) (1.2) (10.8) (15.0) 0.8 (72.9) (3.7) (273.2) (20.1) 1. Free cash flow defined as cash flow from operations less routine capital expenditures and required debt repayments. 14#15Income Statement Adjustments (1) Income Statement Line Item 4Q20 1Q21 2Q21 3Q21 4Q21 (6,541) $ (6,780) (8,701) (4,603) 4 Cost of Service, Excluding Depreciation & Amortization 6,568 8,480 4,464 3,513 4,323 $ 000s Revenue Contingency accrual Other Operating Income CARES Act & State COVID-19 grants Cost of Service COVID-19 costs G&A Acquisition and integration costs COVID-19 costs Acquisition and integration costs COVID-19 costs Pre-acquisition legal settlement Other Items Asset impairment (acquired names) Interest component of certain items Other (income) expense, net (2) Total EPS Impact Net Service Revenue Other Operating Income G&A, Salaries and benefits G&A, Salaries and benefits G&A, Other G&A, Other G&A, Other Asset impairment 1. 2. 507 196 510 1,071 419 45 25 9 60 9 727 1,003 1,783 1,686 891 132 192 151 1,825 139 131 4,152 Interest expense 464 517 Total other (expense) income, net $ 5,815 $ 1,712 $ 469 (31,077) (33,010) $ 451 451 (66) 188 6,858 $ 6,412 $ 0.13 $ 0.04 $ (0.74) $ 0.17 $ 0.15 The financial results for the three-month periods ended December 31, 2020, March 31, 2021, June 30, 2021, September 30, 2021 and December 31, 2021 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period. Other (income) expense, net includes ~$31.1 million gain on Medalogix equity method investment for the three-month period ended June 30, 2021. 15#162022 Guidance 16#17Amedisys 2022 Preliminary Guidance Revenue, EBITDA and EPS guidance ranges for FY 2022 ($M except for EPS) Adjusted Revenue Adjusted EBITDA Adjusted EPS AMED Core Performance $2,274 $2,309 - $301-$311 $5.88 - $6.10 High Acuity Care $56 Total AMED $2,330 $2,365 ($26) $275 - $285 ($0.65) 2022 EBITDA Impacts: • . • Incentive Comp: ~$16M Incremental Contessa: ~$17M Omicron impact: ~$7M • De Novos: $5M • Investments: ~$3M Total: $48M Additional impact from Contessa related to resources needed to service expanded Hospital @ Home JV pipeline, along with resources allocated to new Palliative Care business line. $5.23 - $5.45 Guidance Disclaimer COVID-19 has impacted the operating metrics typically used to forecast both growth and cost assumptions for both core Amedisys and Contessa. We are basing our guidance on our current operating environment. COVID-19 continues to evolve in both the disease itself as well as disruptions to the healthcare systems and the economy. Any future regulations or government interventions, spike in clinicians and BD staff on quarantine, staffing shortages due to current and proposed federal, state and local vaccine mandates, reduction in elective procedures, change in patient behavior and further decline in senior living occupancy could impact our ability to achieve this guidance. 17 17#182022 Guidance Considerations EBITDA impacted by continued Hospice length of stay pressures, incremental Contessa investments, incentive compensation and costs related to Omicron Amedisys Consolidated Home Health Hospice Personal Care • Tax rate 27% • Cash tax rate ~19% • • Diluted share count ~33.2 million shares Capital Expenditures ~$7-$9 million • Salary increase ~2% -3% • Benefits increase ~11% (8% growth/headcount, 3% pricing / claims costs) Overall $8 million investment in business development resources • Excludes future acquisitions, related integration costs and potential share repurchase • Total same store admission growth: ~5% . Continued investment in business development staffing to support growth ~$4 million Continued focus on Quality of Care (Stars and Acute Care Hospitalization rates) • +3.2% rate increase • Total same store admission growth: ~13% • Addition of business development resources to support ADC growth ~ $4 million • +2.0% rate increase • Total billable hours growth: -3% Personal Care Network to drive $2M revenue to ~ Home Health and Hospice combined High Acuity Care • 5 new Joint Venture • arrangements in 2022 ⚫ $56M Revenue • ($26M) EBITDA impact . Total Investments in business of ~$8M • - 2022 Investments Innovations & Projects ($3M) – spend related to automation, workforce optimization and roll out of Medalogix/Muse product • De Novos ($5M) - Expansion of de novo program 18#19Environmental, Social, Governance (E.S.G.) Considerations 19#20Environmental, Social, Governance (E.S.G.) Considerations Sustainable, high-quality, patient focused, home-based care model Environmental, Social, amedisys Governance • Environmental Amedisys is dedicated to the sustainability of our business and the communities in which we serve Environmental health has a strong correlation with physical health A greener fleet - newer vehicles, in circulation for a shorter time, optimize fuel usage. Sophisticated scheduling practices reduce our clinicians' driving time and fuel usage helping to minimize our carbon footprint Virtual care centers, along with flexible working schedules and locations, have created fewer emissions Social Amedisys strives to create an organizational culture and climate in which every individual is valued, all team members have a sense of belonging with one another and to the organization and feel empowered to do their best work Provider of Home Health and Hospice services to frail, elderly patients in their most preferred care location - their homes Highest quality Home Health company as measured by Quality of Patient Care Star scores (4.33 Stars) The Amedisys Foundation was formed to provide support to our patients and employees. The Amedisys Foundation has two funds: the Patients' Special Needs Fund and the Amedisys Employees 1st Fund. The Patients' Special Needs Fund provides financial assistance to our home health, hospice and personal care patients during a difficult time Governance Amedisys has a culture of compliance starting with oversight from the Board of Directors and cascading down to the care center level Our Board of Directors operates several sub-committees including: • • Quality Committee Compliance Committee Audit Committee Compensation Committee Nominating & Corporate Governance Committee Nominating and Corporate Governance Committee oversees our strategy on corporate social responsibility, including evaluating the impact of Company practices on communities and individuals, and develops and recommends to our Board of Directors for approval matters relating to the Company's corporate social responsibility and ESG considerations 20